Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 4Active not recruiting 3Completed 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 3Lymphoma 3Lymphoma, B-Cell 2Recurrence 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × polatuzumab vedotin × Clear all
NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Hoffmann-La Roche

Phase 1 Completed
111 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03677141 2024-12-18

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1/2 Completed
117 enrolled 26 charts
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡